ACTB-1011

N/A

Report date: 2025/02/01 20:00:06

NME

Base Information

Drug NameACTB-1011

Drug Alias NameABL/Kit/VEGFR inhibitor (ACT Biotech)Bcr/ABL program (ACT Biotech)ABL tyrosine kinase inhibitor (ACT Biotech)ACTB-1011

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionStem cell growth factor receptor inhibitorsVascular endothelial growth factor receptor antagonistsBcr-Abl tyrosine kinase inhibitors

TargetsStem cell growth factor receptorBcr-Abl tyrosine kinaseVascular endothelial growth factor receptor

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAct Biotech Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAct Biotech Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A